Showing results (351-360 of 457) with videos related to
Sort By:
Pageof 46
Archives of Osteoporosis|January 25, 2011
Baseline observations from the POSSIBLE EU® study: characteristics of postmenopausal women receiving bone loss medicationsNick Freemantle, Cyrus Cooper, Christian Roux, et al.Joint Bone Spine|July 21, 2026
Clinical stability despite progressive fatty infiltration in patients over 50 years old with full-thickness rotator cuff tearsTiphany Neel, Thierry Tavernier, Marie-Martine Lefevre-Colau, et al.Journal of Agricultural and Food Chemistry|July 1, 2022
Nasal Odorant Competitive Metabolism Is Involved in the Human Olfactory ProcessAline Robert-Hazotte, Philippe Faure, Franck Ménétrier, et al.The Journal of Clinical Endocrinology and Metabolism|August 18, 2021
Prevalence of Enthesopathies in Adults With X-linked Hypophosphatemia: Analysis of Risk FactorsJulia Herrou, Axelle Salcion Picaud, Louis Lassalle, et al.The EMBO Journal|January 17, 2016
Non-acidic activation of pain-related Acid-Sensing Ion Channel 3 by lipidsSébastien Marra, Romain Ferru-Clément, Véronique Breuil, et al.Arthritis & Rheumatology (Hoboken, N.J.)|March 15, 2022
Do Glucocorticoid Injections Increase the Risk of Knee Osteoarthritis Progression Over 5 Years?Augustin Latourte, Anne-Christine Rat, Abdou Omorou, et al.Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|April 7, 2006
Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factorsChristian Roux, Jean-Yves Reginster, Jacques Fechtenbaum, et al.Joint Bone Spine|October 4, 2011
Epidemiogenetic study of French families with Paget's disease of boneLaëtitia Michou, Corinne Collet, Jean Morissette, et al.Drugs & Aging|May 11, 2019
Safety of Topical Non-steroidal Anti-Inflammatory Drugs in Osteoarthritis: Outcomes of a Systematic Review and Meta-AnalysisGermain Honvo, Victoria Leclercq, Anton Geerinck, et al.Bone|October 9, 2007
Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosisPierre D Delmas, Michael R McClung, José R Zanchetta, et al.Pageof 46